Literature DB >> 26702769

Disruption of redox homeostasis and carcinogen metabolizing enzymes changes by administration of vitamin E to rats.

Fabio Vivarelli1, Donatella Canistro2, Paola Franchi3, Andrea Sapone4, Andrea Vornoli5, Clara Della Croce6, Vincenzo Longo6, Marco Lucarini3, Moreno Paolini4.   

Abstract

AIMS: A large meta-analysis of randomized clinical trials has seriously questioned chemoprevention based on vitamins including vitamin E (VE), and an increased risk for cancer among long-term users was actually seen. However, the mechanism underlying these findings still remain unknown. To clarify the mechanism, in an in vivo model we studied the putative disruption of redox homeostasis and the perturbation of carcinogen metabolizing enzymes determined by VE. MAIN
METHODS: Male Sprague-Dawley rats were treated ip with either 100 or 200mg/kg b.w. daily for 7 or 14 consecutive days. Controls received vehicle only. Cytochrome P450 (CYP) content, CYP-reductase, CYP-linked monooxygenases, as well as phase-II and the antioxidant enzymes catalase and NAD(P)H: quinone reductase were investigated in both liver and kidney. Free radical species in tissue subcellular preparations were measured by electronic paramagnetic resonance (EPR) spectroscopy coupled to a radical probe technique. KEY
FINDINGS: No substantial changes of hepatic xenobiotic metabolism enzymes were determined by VE. Conversely, a powerful booster effect of various renal phase-I carcinogen bioactivating enzymes at both dosages and observational times was recorded. While no relevant changes of post-oxidative phase-II reactions were found in the liver, a significant inactivating effect was caused by VE in renal tissues. Antioxidant enzymes were found mainly downregulated by the treatment. In the kidney, a marked free radical over-generation linked to CYP induction was observed. SIGNIFICANCE: This study proved that VE acts as a co-carcinogen and pro-oxidant agent. Such epigenetic mechanisms may contribute to explain the harmful outcomes observed in humans.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antioxidant enzymes; Chemopreventive agent; Cytochrome P450; Free radical species; Phase II enzymes; Vitamin E

Mesh:

Substances:

Year:  2015        PMID: 26702769     DOI: 10.1016/j.lfs.2015.12.033

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

1.  Vitamin C and Vitamin E Mitigate the Risk of Pancreatic Ductal Adenocarcinoma from Meat-Derived Mutagen Exposure in Adults in a Case-Control Study.

Authors:  Donghui Li; Hongwei Tang; Peng Wei; Jiali Zheng; Carrie R Daniel; Manal M Hassan
Journal:  J Nutr       Date:  2019-08-01       Impact factor: 4.798

2.  Geraniol Pharmacokinetics, Bioavailability and Its Multiple Effects on the Liver Antioxidant and Xenobiotic-Metabolizing Enzymes.

Authors:  Barbara Pavan; Alessandro Dalpiaz; Luca Marani; Sarah Beggiato; Luca Ferraro; Donatella Canistro; Moreno Paolini; Fabio Vivarelli; Maria C Valerii; Antonietta Comparone; Luigia De Fazio; Enzo Spisni
Journal:  Front Pharmacol       Date:  2018-01-25       Impact factor: 5.810

3.  An excess dietary vitamin E concentration does not influence Nrf2 signaling in the liver of rats fed either soybean oil or salmon oil.

Authors:  Klaus Eder; Marina Siebers; Erika Most; Susan Scheibe; Norbert Weissmann; Denise K Gessner
Journal:  Nutr Metab (Lond)       Date:  2017-11-16       Impact factor: 4.169

4.  E-cigarettes induce toxicological effects that can raise the cancer risk.

Authors:  Donatella Canistro; Fabio Vivarelli; Silvia Cirillo; Clara Babot Marquillas; Annamaria Buschini; Mirca Lazzaretti; Laura Marchi; Vladimiro Cardenia; Maria Teresa Rodriguez-Estrada; Maura Lodovici; Caterina Cipriani; Antonello Lorenzini; Eleonora Croco; Silvia Marchionni; Paola Franchi; Marco Lucarini; Vincenzo Longo; Clara Maria Della Croce; Andrea Vornoli; Annamaria Colacci; Monica Vaccari; Andrea Sapone; Moreno Paolini
Journal:  Sci Rep       Date:  2017-05-17       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.